Pharmaceutical Foams

Foams can be produced using two distinct technologies:

  • In an aerosol using propellant gas, the formulation consists of an emulsion. The creamy foam obtained is suitable for damaged or sensitive skin (e.g., psoriasis or atopy).

Gattefosse propellant-foam

  • In a propellant-free device, the formulation consists of a microemulsion. The light texture obtained is suitable for quick absorption without residue and is convenient for hair-bearing skin. It may, for example, be used with disinfectant or anti-inflammatory drugs.

Gattefosse propellant-free-foam

Excipients for propellant device emulsion formulation:

Tefose® 63 is an O/W emulsifier with foaming capacity and high mucosal tolerance. It is often used in combination with Labrafil® M 1944 CS as a co-emulsifier and Transcutol® P as solvent.

Excipients for propellant-free device micro-emulsion formulation:

Labrasol® is a good solubilizer with foaming capacity. It is often used in combination with Plurol® Oleique CC 497 as cosurfactant and Labrafac® Lipophile WL 1349 as an oily vehicle and emollient.

 

ft_pf_pharmaceutical-foamGattefossé can provide formulation tips for pharmaceutical foams using propellant and propellant-free devices, guidelines on how to formulate and select excipients, and case studies with model drugs.

Find out more on in our white paper.

 

RELATED DOCUMENTS